Pharmacokinetic and Pharmacodynamic Modeling of Cyadox Against Clostridium Perfringens in Swine.

Lei Yan,Shuyu Xie,Dongmei Chen,Yuanhu Pan,Yanfei Tao,Wei Qu,ZhenLi Liu,Zonghui Yuan,Lingli Huang
DOI: https://doi.org/10.1038/s41598-017-03970-9
IF: 4.6
2017-01-01
Scientific Reports
Abstract:The purpose of this study was to evaluate the activity of cyadox against Clostridium perfringens in swine and optimize the dosage regimen using ex vivo pharmacokinetic-pharmacodynamic (PK-PD) modeling. After oral administration, the ileum fluid of pigs containing the free cyadox was collected by implanted ultrafiltration probes. The T max , AUC 24h , and CL/F of free cyadox in the ileum fluid were 1.96 h, 106.40 μg/h/mL, and 0.27 L/kg/h, respectively. Cyadox displayed a concentration-dependent killing action against C . perfrignens . The minimum inhibitory concentration (MIC) of cyadox against 60 clinical isolates ranged from 0.5 to 8 μg/mL, with MIC 50 and MIC 90 values of 2 and 4 μg/mL, respectively. The MIC was 2 μg/mL against the pathogenic C . perfrignens isolate CPFK122995 in both broth and ileum fluid. According to the inhibitory sigmoid E max modeling, the AUC 24h /MIC ratios of ileum fluid required to achieve the bacteriostatic, bactericidal, and virtual bacterial elimination effects were 26.72, 39.54, and 50.69 h, respectively. Monte Carlo simulations for the 90% target attainment rate (TAR) predicted daily doses of 29.30, 42.56, and 54.50 mg/kg over 24 h to achieve bacteriostatic, bactericidal, and elimination actions, respectively. The results of this study suggest that cyadox is a promising antibacterial agent for the treatment of C . perfringens infections, and can be used to inform its clinical use.
What problem does this paper attempt to address?